stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Shares outstanding
Xenon Pharmaceuticals Inc.'s shares outstanding at the end of fiscal 2025 was $79.3M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $99.6M. Over the past ten years it has ranged from $14.3M (fiscal 2015) to $79.3M (fiscal 2025) — the current reading is the highest in ten years. Xenon Pharmaceuticals Inc. ranks 153rd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $79.3M | 1.74% |
| FY2024 | $77.9M | 16.45% |
| FY2023 | $66.9M | 10.48% |
| FY2022 | $60.5M | 38.77% |
| FY2021 | $43.6M | 26.30% |
| FY2020 | $34.5M | 33.16% |
| FY2019 | $25.9M | 33.53% |
| FY2018 | $19.4M | 7.91% |
| FY2017 | $18.0M | 16.19% |
| FY2016 | $15.5M | 8.48% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $99.6M | 14.04% |
| Mar 2026 | $87.3M | 10.21% |
| Dec 2025 | $79.3M | 0.01% |
| Sep 2025 | $79.2M | 0.37% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. compare | $450.2M |
| ABCL AbCellera Biologics Inc. compare | $305.6M |
| RLAY Relay Therapeutics, Inc. compare | $202.8M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| TNGX Tango Therapeutics, Inc. compare | $149.9M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| XENE Xenon Pharmaceuticals Inc. | $99.6M |
| IRON Disc Medicine, Inc. compare | $38.7M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement